Company profile: ANA Therapeutics
1.1 - Company Overview
Company description
- Provider of biotech therapeutics developing a novel coronavirus vaccine and niclosamide-based treatments to enable medical practitioners to treat patients with COVID-19; founded in 2020 and headquartered in Foster City, California.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to ANA Therapeutics
Cempra
HQ: United States
Website
- Description: Provider of medicines for the treatment of bacterial infections and chronic illnesses.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cempra company profile →
Tevogen Bio
HQ: United States
Website
- Description: Provider of immunotherapy solutions focused on T cell therapies for infectious diseases, cancers, and neurological disorders. Offerings include the ExacTcell platform utilizing CD8+ cytotoxic T lymphocytes; TVGN 489, an investigational therapy for high-risk COVID-19 and potential Long COVID; Tevogen.AI to accelerate development and target detection; and the TCTL trial in adults with newly diagnosed COVID-19.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tevogen Bio company profile →
Arbutus Biopharma
HQ: Canada
Website
- Description: Provider of biopharmaceutical therapies for hepatitis B virus (HBV), including Imdusiran (AB-729), a subcutaneously delivered RNAi therapeutic designed to reduce HBV viral antigens such as HBsAg, and AB-101, an oral PD-L1 inhibitor intended to reawaken HBV-specific T cells by blocking the PD-1/PD-L1 protein-protein interaction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arbutus Biopharma company profile →
Enanta Pharmaceuticals
HQ: United States
Website
- Description: Provider of small-molecule anti-infective drug R&D, discovering and developing therapies including MAVYRET (glecaprevir/pibrentasvir), a hepatitis C virus protease inhibitor regimen requiring only eight weeks of treatment; EDP-514, a novel hepatitis B core inhibitor; zelicapavir (EDP-938), an RSV N-protein inhibitor in Phase 2 for pediatric and adult patients; EDP-323, an RSV L-protein inhibitor; and EDP-235, a 3CL protease inhibitor for COVID-19.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Enanta Pharmaceuticals company profile →
Elion Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology solutions focused on treating life-threatening IFIs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Elion Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for ANA Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to ANA Therapeutics
2.2 - Growth funds investing in similar companies to ANA Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for ANA Therapeutics
4.2 - Public trading comparable groups for ANA Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →